Loading clinical trials...
Loading clinical trials...
A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression
Conditions
Interventions
ARX788
Locations
12
United States
USC Norris Cancer Hospital
Los Angeles, California, United States
UCLA Hematology-Oncology
Santa Monica, California, United States
Washington University School of Medicine
St Louis, Missouri, United States
Cleveland Clinic
Cleveland, Ohio, United States
Baylor Sammons Cancer Center
Dallas, Texas, United States
Research Site
East Albury, New South Wales, Australia
Start Date
March 20, 2018
Primary Completion Date
September 13, 2023
Completion Date
October 18, 2023
Last Updated
February 1, 2024
NCT04570423
NCT06926283
NCT07177937
NCT07489378
NCT07181681
NCT07360314
Lead Sponsor
Ambrx, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions